DocumentRX-3284
Issued
Read3 min

Bora Books $437M CDMO Contracts, Defers 25 Batches on FDA Upgrades

Bora booked $437M in new CDMO contracts across 24 projects as Q3 revenue rose 34.3% to $196.2M, but FDA-required RABS-to-isolator conversions defer 25 batches to 2027 and gross margin fell to 39%.

TAG T-4813 · 662 words on the filing

Bora Secures USD 437M in CDMO Deals as FDA-Driven Delays Pressure Q3 Margins - GeneOnline
Bora Secures USD 437M in CDMO Deals as FDA-Driven Delays Pressure Q3 Margins - GeneOnlinePublicDomainPictures / pixabay

Summary of findings

  • Bora signed ~USD 437M in new CDMO contracts YTD across 24 projects; rolling backlog USD 340M
  • Q3 revenue NTD 6.453B (USD 196.2M), up 34.3% YoY; gross margin fell to 39% from 45%
  • ~25 injectable batches deferred to 2027 amid FDA-required RABS-to-isolator conversion; remediation plan due Q4 2026–Q1 2027
  • Rockville site made 8 commercial batches in first integrated quarter vs 13 in all of 2025
  • Net debt-to-equity hit 97.3% at Q3-end vs 70.7% at start of 2026

By Grace Kim

Bora Pharmaceuticals booked approximately USD 437 million in new CDMO contracts year to date across 24 projects, even as FDA-mandated upgrades at its Maryland injectable plant pushed roughly 25 manufacturing batches into 2027. The Taiwan-based company (6472.TW) reported record third-quarter revenue of NTD 6.453 billion (USD 196.2 million), up 34.3% year over year, but gross margin fell to 39% from 45% a year earlier.

Chairman Bobby Sheng said mid-term visibility from 2027 onward is "the highest in company history." The takeaway: Bora is winning record business while its plants struggle to convert it into profit.

What drove Q3 revenue?

The CDMO segment generated NTD 2.085 billion (USD 63.4 million), up 16.9% year over year but down 1.5% sequentially; formulation output rose 16%, the largest sequential gain since 2025. The rolling 12-month order backlog stood at USD 340 million, including USD 50 million tied to the Rockville biologics site. New signings cover future multi-year work and will not appear in quarterly results immediately. Bora manufactured roughly 440 million doses during the quarter.

Pharmaceutical sales contributed NTD 3.302 billion (USD 100.4 million), up 9.3% year over year, which Sheng called the segment's "strongest quarterly growth in the past 18 months." Specialty and branded revenue ran 22.4% above the 2025 quarterly average, and the vigabatrin portfolio logged its seventh straight quarter of sequential growth. Vigafyde, for infantile spasms, holds above 50% market penetration, with a 70–80% target. The quarter also included one-time Megestrol Acetate licensing income outside China, a nonrecurring item inflating the comparison.

What does the FDA remediation require?

The FDA requested safety improvements to restricted access barrier system (RABS) lines at the Maryland injectable facility. Bora is converting three RABS lines to isolator technology and expects to submit a comprehensive remediation plan between Q4 2026 and Q1 2027. The site currently runs two isolator lines, has completed four PPQ batches, and anticipates three additional technology-transfer projects in 2027. Coordination covers more than a dozen customers. Next year's production lines are already close to fully booked. Sheng said Bora intends to charge customers for the conversion, though the financial impact of deferred batches remains undetermined.

Why did margins compress?

Consolidated gross profit rose 16.5% to NTD 2.529 billion; operating profit gained only 2.4% to NTD 1.09 billion, and net income rose 2.7% to NTD 654 million. CFO Alice Wang cited acquisition-related changes, generic competition, and postponed injectable activity. Management expects gross margin to recover above 40% in 2027 as utilization improves. Net debt-to-equity reached 97.3% at quarter-end, versus 70.7% at the start of 2026, against cash of NTD 5.594 billion.

What is the biologics network status?

The Rockville facility, acquired from MacroGenics for USD 122.5 million, produced eight commercial batches in its first integrated quarter — approaching the 13 batches made through all of 2025 — and reached positive cash flow excluding one-time costs. San Diego capacity uptake ran slower than planned, prompting a realignment of biologics assets to finish within two quarters. The Rockville–San Diego–Zhubei "golden triangle" is designed to let customers move programs between sites without changing partners.

What comes next?

Sheng declared: "We are now in the final stretch of this investment cycle." Bora has deployed USD 55 million in cumulative capital, over half toward specialized manufacturing. The Maple Grove facility holds a long-term agreement with a top-20 pharma company, with material revenue expected late 2027 to 2028. A group procurement function and MSAT team were established in 2026. "The Group will operate under one financial discipline with shared capabilities," Sheng said. A Tanvex BioPharma cooperation is expected to cut that affiliate's annual cash outflow by roughly one-quarter, or more than USD 10 million, in 2027. The takeaway: 2027 tests whether record contracts translate into margin recovery.

via FDA industry wire (Google News) (Source)

Share this article:

More from Grace Kim

Grace Kim

Show full bio

Market editor covering companies, deals and strategy in global pharmaceutical industry at PharmInsider.

7 articles

Linked filings

  1. T-7393
  2. K-2547
  3. E-6700
  4. K-8919
  5. K-5457

Next filing »